Phase 3 Cardiomyopathy Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with dilated cardiomyopathy (an enlarged, weakened heart) linked to specific genetic variants (in genes called MYH7, TTN, or similar), or where the condition runs in the family
• People whose heart failure symptoms fall into a moderate-to-severe range (Class II to IV on a standard medical scale) and whose symptoms have been stable for at least one month before the screening visit
• People whose heart has at least mild enlargement of the left chamber, and whose heart can be clearly seen on an ultrasound scan
• People whose heart's pumping strength (called ejection fraction) is 45% or below
• People who have been on the highest doses of standard heart failure medications they can tolerate, and those doses have been stable for at least four weeks before the first visit
• People whose enlarged, weakened heart is not caused by substance use, or by conditions such as amyloidosis, sarcoidosis, or other secondary causes
• People who are able to complete an upright exercise breathing test, and whose oxygen uptake during peak effort is 80% or less of what would be expected for a healthy person of the same profile, with sufficient effort shown during the test (confirm with trial site)

Who may not be able to join:

• People whose weakened heart is caused mainly by blocked coronary arteries, long-term heart valve disease, or another underlying condition, as determined by the treating investigator
• People who have had a significant heart event in the past 90 days, such as a heart attack, a procedure to open blocked heart arteries, heart bypass surgery, or a hospital stay related to heart failure or fluid-removal treatment given through a drip
• People who have certain heart rhythm problems that could interfere with accurate heart ultrasound readings, such as poorly controlled atrial fibrillation or irregular heartbeats occurring frequently enough to affect measurements
• People who have an unstable or untreated serious abnormal heart rhythm, such as ventricular tachycardia or ventricular fibrillation
• People who have been diagnosed with any type of cancer within the five years before the screening visit
• People with severely reduced kidney function, as measured by a specific blood test result falling below a set threshold at the time of screening
• People who have any other significant medical condition, disorder, or disease that, in the investigator's or sponsor's opinion, could affect safety or interfere with the study
• People who have previously had a heart transplant, or for whom a heart transplant is expected within the next six months
• People who are currently receiving, or are expected to need, advanced heart treatments such as long-term heart-strengthening medication given through a drip, heart device implantation, resynchronisation therapy, or major surgery within six months
• People who have significantly abnormal blood test results at the time of screening

Important: Always verify eligibility with the trial site directly before applying.